Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPRAZOLAM vs LEVOPROME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.
Generalized anxiety disorder,Panic disorder with or without agoraphobia,Anxiety (off-label),Insomnia (off-label),Chemotherapy-induced nausea and vomiting (off-label),Premenstrual dysphoric disorder (off-label)
Psychotic disorders,Schizophrenia,Acute mania,Nausea and vomiting,Intractable hiccups
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Terminal elimination half-life is approximately 24 hours (range 12–36 hours). Accumulation occurs with repeated dosing, requiring dose adjustment in hepatic impairment.
Primarily hepatic via CYP3A4; major metabolites are alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive).
Hepatic via CYP2D6, CYP3A4; active metabolites include methotrimeprazine sulfoxide, N-desmethylmethotrimeprazine.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Primarily renal (approx. 70% as conjugated metabolites, <1% unchanged), with biliary/fecal excretion (approx. 20%).
80% (primarily to albumin, minor to α1-acid glycoprotein)
>99% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.8 L/kg (range 0.6-1.2 L/kg); clinical meaning: moderate tissue distribution, reflects lipophilicity; higher Vd in obesity
Approximately 7 L/kg (range 5–10 L/kg), indicating extensive tissue distribution.
Oral: 90% (immediate-release); extended-release: approximately 90% relative to immediate-release; sublingual: approximately 75-80% of oral
Oral: 40–50% (first-pass effect); Intramuscular: 70–80%.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 50% or consider alternative.
Cr Cl 10-50 m L/min: Administer 75% of usual dose; Cr Cl <10 m L/min: Administer 50% of usual dose.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 25-50%; Child-Pugh Class C: Avoid use.
Not FDA-approved for <18 years; limited data: 0.125 mg/kg/dose orally 3 times daily (max 0.02 mg/kg/dose) for panic disorder in adolescents.
Children >12 years: 0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 2 mg/kg/day. Not recommended for children under 12 years.
Start with 0.25 mg orally 2-3 times daily; increase slowly due to increased sensitivity and risk of falls; maximum 2 mg/day.
Initial dose: 12.5 to 25 mg intramuscularly; titrate cautiously due to increased sensitivity and risk of orthostatic hypotension.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Increased mortality in elderly patients with dementia-related psychosis; risk of tardive dyskinesia; neuroleptic malignant syndrome (NMS).
Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; respiratory depression; worsening of depression or suicidal ideation; use in patients with acute narrow-angle glaucoma; impaired motor and cognitive performance; risk of severe allergic reactions.
Neuroleptic malignant syndrome, tardive dyskinesia, hypotension, seizures, anticholinergic effects, QT prolongation, agranulocytosis, photosensitivity, elevation of prolactin levels.
Concurrent use with ketoconazole or itraconazole; hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; severe hepatic impairment; pregnancy (especially first trimester) and breastfeeding.
Comatose states, CNS depression, bone marrow suppression, pheochromocytoma, hypersensitivity to phenothiazines, concurrent use with high-dose CNS depressants.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing alprazolam levels and risk of toxicity. Avoid alcohol. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they may increase serum levels of methotrimeprazine. Limit caffeine intake as it may exacerbate side effects like restlessness. No specific food restrictions otherwise.
First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) with chronic high-dose use. Late third trimester: Risk of neonatal withdrawal syndrome.
First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations; risk of neonatal extrapyramidal symptoms and jaundice with third-trimester use.
Excreted into breast milk; M/P ratio approximately 0.3-0.5. Relative infant dose ~2-3% of maternal weight-adjusted dose. Clinical significance: low but may cause sedation, poor feeding, or withdrawal in neonates. Use caution, monitor infant for lethargy and weight gain.
Levofloxacin (levoprome) is excreted in human milk; M/P ratio approximately 0.8. Avoid breastfeeding during therapy due to potential adverse effects on infant cartilage development.
Increased clearance and volume of distribution in pregnancy may require dose up-titration. Monitor clinical response; consider increasing dose by 20-50% in second and third trimesters. Avoid abrupt discontinuation; taper if needed. Use lowest effective dose for shortest duration.
No dosage adjustment required based on pregnancy-related pharmacokinetic changes; however, use only if clearly needed due to theoretical risks to fetus.
Alprazolam is a short-acting benzodiazepine with a rapid onset. Due to its high potency and short half-life, it carries a high risk of dependence and withdrawal. Avoid in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Use with caution in patients with history of substance abuse. Taper gradually to prevent rebound anxiety and seizures. Onset of action is 15-30 min orally; peak effect at 1-2 hours.
Levoprome (methotrimeprazine) is a phenothiazine neuroleptic with potent analgesic properties. It may cause significant hypotension, especially in elderly or hypovolemic patients; use with caution and monitor blood pressure. Extrapyramidal symptoms are less common than with typical antipsychotics but may occur. Avoid subcutaneous extravasation due to tissue irritation.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants as they can cause severe sedation and respiratory depression.,Do not drive or operate heavy machinery until you know how alprazolam affects you; it may cause drowsiness or dizziness.,Do not stop abruptly; withdrawal symptoms can include anxiety, insomnia, seizures, and life-threatening reactions.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any worsening of depression or suicidal thoughts immediately.
This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Avoid alcohol and other central nervous system depressants.,Rise slowly from sitting or lying positions to prevent fainting.,Report any unusual muscle movements or stiffness to your healthcare provider.,Use sunscreen and protective clothing as this drug may increase sensitivity to sunlight.
"Alprazolam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tetracaine, an ester-type local anesthetic. This additive or synergistic interaction can lead to excessive sedation, respiratory depression, and hypotension, particularly in elderly or debilitated patients. Concurrent use may also increase the risk of seizures due to tetracaine's proconvulsant activity at high doses, which is compounded by alprazolam's withdrawal-associated seizure risk."
"Co-administration of alprazolam, a benzodiazepine, with indinavir, a potent CYP3A4 inhibitor, significantly increases alprazolam's serum concentration and half-life via reduced hepatic metabolism, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Conversely, indinavir levels may be modestly increased due to competition for metabolism. This interaction poses a risk of severe central nervous system depression and should be avoided if possible."
"Concurrent use of alprazolam, a benzodiazepine with central nervous system depressant effects, and proparacaine, a topical ophthalmic anesthetic that can be systemically absorbed, may lead to additive CNS depression. This interaction can manifest as increased sedation, dizziness, confusion, or respiratory depression, especially in patients with compromised respiratory function or those receiving high doses of either agent. Clinicians should exercise caution when combining these drugs due to the potential for enhanced adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPRAZOLAM vs LEVOPROME, answered by our medical review team.
ALPRAZOLAM is a Benzodiazepine that works by Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.. LEVOPROME is a Phenothiazine Antipsychotic that works by Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPRAZOLAM and LEVOPROME depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPRAZOLAM is: 0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.. The standard adult dose of LEVOPROME is: 25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPRAZOLAM and LEVOPROME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPRAZOLAM is classified as Category D/X. First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome. LEVOPROME is classified as Category C. First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations;. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.